Colon, Phase II
A Phase 2 Trial to Evaluate the Safety and Efficacy of Combination Therapies in Patients With Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric)
Volunteers
Health Professionals
What is the purpose of this trial?
This is a Phase 2, open-label, parallel 3-cohort, multicenter study to evaluate the safety and preliminary clinical activity of treatment combinations with and without chemotherapy in participants with locally advanced unresectable or metastatic gastric, GEJ, and esophageal adenocarcinoma. Chemotherapy will consist of FOLFOX (oxaliplatin, leucovorin, fluorouracil).
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Andrea Brennan
- Ashita Talsania, MRCP, MBBS
- David Witt, MD
- Elan Gorshein, DO, JD, MPH
- Jacquelyne Gaddy, MD, MSc, MSCR
- Jane Kanowitz, MD
- Jeremy Kortmansky, MD
- Justin Persico, MD
- Karen Ann Hammond, DNP, APRN, ACNP (BC)
- Katelyn Scott
- Kert Sabbath, MD, FACP
- Kristen Hoxie
- Larisa Fleysher
- Laura Van Metre Baum, MD, MPH
- M. Sung Lee, MD
- Michael Cecchini, MD
- Michael Cohenuram, MD
- Michael Grant, MD
- Neal Fischbach, MD
- Pamela L. Kunz, MD
- Renee Moye
- Samantha Couillard
- Sarah Carlson
- Sarah Thomen, APRN
- Sharynn Hall, MD, PhD
- Stacey Stein, MD
- Stephanie Paine, APRN
- Su Hsien Lim, MD
- Teresa White
- Vanna Dest
- Victor Chang, MD
- Virginia Syombathy
- Last Updated06/30/2024
- Study HIC#2000033245